MLLT3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL12467146	0.64	4/20
SCHEMBL214952	0.50	4/20
SCHEMBL215564	0.49	4/20
SCHEMBL6813380	0.45	4/20
SCHEMBL11931686	0.67	3/20
Hydrochloric Acid (SCHEMBL658509)	0.48	3/20
SCHEMBL16824464	0.43	3/20
SCHEMBL216157	0.42	3/20
SCHEMBL15008043	0.41	3/20
SCHEMBL17117167	0.76	2/20
SCHEMBL11931680	0.74	2/20
SCHEMBL11937745	0.63	2/20
SCHEMBL9911612	0.61	2/20
SCHEMBL15099490	0.59	2/20
SCHEMBL3670760	0.59	2/20
SCHEMBL9911636	0.57	2/20
SCHEMBL14160551	0.56	2/20
SCHEMBL9911610	0.54	2/20
SCHEMBL9911606	0.53	2/20
SCHEMBL10051964	0.52	2/20

Clinical trials — most relevant to MLLT3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia	PHASE4	UNKNOWN
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia	PHASE3	COMPLETED
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients	PHASE3	RECRUITING
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	PHASE3	COMPLETED
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML	PHASE2	RECRUITING
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes	PHASE2	RECRUITING
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.	PHASE2	COMPLETED
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia	PHASE2	COMPLETED
Cord Blood Transplant in Adults With Blood Cancers	PHASE2	RECRUITING
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation	PHASE1/PHASE2	RECRUITING
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation	PHASE2	COMPLETED
GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.	PHASE2	UNKNOWN
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease	PHASE2	COMPLETED
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia	PHASE1	RECRUITING
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies	PHASE1	RECRUITING
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving	PHASE1	COMPLETED
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	ACTIVE_NOT_RECRUITING
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene	PHASE1	COMPLETED
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia	PHASE1	ACTIVE_NOT_RECRUITING
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies	PHASE1	WITHDRAWN
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.	nan	RECRUITING
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia	nan	COMPLETED
Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia	nan	COMPLETED
Triple Negative Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL	nan	RECRUITING
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia	nan	UNKNOWN
Effect of 2nd Gen TKI in CML	nan	COMPLETED
Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia	nan	COMPLETED
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MLLT3 binder may also engage these)

Protein	Name	Similarity
A2AM29	—	1.000	A2AM29 →
MLLT1	Protein ENL	0.992	landscape →
Q92539	—	0.992	Q92539 →
Q14AX6	—	0.992	Q14AX6 →
P70047	—	0.992	P70047 →
Q24595	—	0.991	Q24595 →
Q6DRG7	—	0.991	Q6DRG7 →
P30181	—	0.990	P30181 →
Q62901	—	0.990	Q62901 →
A0JMK9	—	0.990	A0JMK9 →
Q9NQW6	—	0.990	Q9NQW6 →
Q86TC9	—	0.989	Q86TC9 →
Q80TZ9	—	0.989	Q80TZ9 →
P97868	—	0.989	P97868 →
Q9VCP0	—	0.989	Q9VCP0 →
Q90YL3	—	0.989	Q90YL3 →
Q1LYM3	—	0.989	Q1LYM3 →
Q3MJK5	—	0.989	Q3MJK5 →
Q14693	—	0.989	Q14693 →
Q66J90	—	0.989	Q66J90 →
Q8K0V4	—	0.989	Q8K0V4 →
Q6DD45	—	0.989	Q6DD45 →
A6QP06	—	0.989	A6QP06 →
KMT5B	Histone-lysine N-methyltransferase KMT5B	0.989	landscape →
Q7YZA2	—	0.989	Q7YZA2 →
A0A5E4M3Q4	—	0.989	A0A5E4M3Q4 →
Q10728	—	0.988	Q10728 →
E1BB50	—	0.988	E1BB50 →
Q9FJ79	—	0.988	Q9FJ79 →
ZMYND8	MYND-type zinc finger-containing chromatin reader ZMYND8	0.988	landscape →